Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mesoblast Limited ( (AU:MSB) ) just unveiled an announcement.
Mesoblast Limited announced a significant milestone with the FDA approval and successful commercial launch of Ryoncil®, the first mesenchymal stromal cell product approved in the US for treating SR-aGvHD in children. The company reported a substantial increase in revenue driven by Ryoncil®’s launch, with plans to expand its indications and explore new markets. Mesoblast’s strategic initiatives, including strengthening its board and expanding insurance coverage for Ryoncil®, position it for growth in the biotechnology sector.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$2.97 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines focused on treating inflammatory diseases. The company specializes in developing innovative off-the-shelf cellular medicines, with a product portfolio that includes Ryoncil®, the only FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft-versus-host disease (SR-aGvHD). Mesoblast is also exploring potential blockbuster indications such as heart failure and chronic low back pain.
Average Trading Volume: 4,821,241
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$3.15B
See more data about MSB stock on TipRanks’ Stock Analysis page.